This Is By Far My #1 Income Stock

Analyst Targets

• Goldman Sachs: Buy, target $1,413
• Berenberg Bank: Buy, target $1,400
• Truist Financial: Buy, target $1,376
• Bernstein: Outperform, target $1,385

The Machine Behind the Deals

Eli Lilly’s free cash flow was about $18.2 billion on a trailing twelve-month basis through June 2026, up from about $8.97 billion for full-year 2025. That compounding cash engine is what makes a thirteen-acquisition year mathematically possible. The company has deployed roughly $32 billion on biotech targets in 2026 alone, recycling GLP-1 profits directly into clinical-stage pipelines it could not have built organically in time.

Q3 earnings land October 29, 2026. Before that number arrives, it is worth understanding exactly what $32 billion bought, and whether the structure of those bets is coherent or simply opportunistic.

The Acquisition Map

The two largest deals frame the strategy clearly. Centessa Pharmaceuticals cost up to $7.8 billion, with $6.3 billion upfront. Kelonia Therapeutics cost up to $7 billion, with $3.25 billion upfront, giving Lilly engineered lentiviral-based particles designed to deliver genetic cargo directly to T cells inside the body. Both are mechanism-led bets on platform technology, not single-asset plays.

Below those anchors sits a diverse second tier. Orna Therapeutics, acquired for up to $2.4 billion, brings circular RNA therapeutics and an in vivo CAR-T candidate for autoimmune diseases. Ventyx Biosciences, closed in March for about $1.2 billion, adds small-molecule NLRP3 inhibitors targeting inflammation across a range of disease areas. Ajax, acquired for up to $2.3 billion, contributes a Phase 1 JAK2 inhibitor for myelofibrosis.

Three infectious disease acquisitions in late May added another up to $3.8 billion: Curevo’s Phase 2 shingles vaccine candidate, LimmaTech’s Phase 1 Staphylococcus aureus vaccine, and Vaccine Company’s preclinical Epstein-Barr virus program. Merida Biosciences, the thirteenth deal, reached up to $2.875 billion for a Phase 1 lead asset plus platform, announced August 31, 2026.

The Real Question Is Execution Timing

The structural risk here is not capital. With Q2 revenue up 48% year over year and guidance raised to $85 to $87 billion for the full year, Lilly can afford the spending. The risk is milestone compression. Most of these deals are structured with significant contingent payments tied to clinical and regulatory events. Acquired in-process R&D charges already cut $3.03 per share from Q2 EPS. That figure will grow as more deals close.

Lilly is essentially running a clinical trial rollup: buy mid-stage assets before Phase 3 data de-risks them, absorb the milestones inside a balance sheet large enough to weather binary outcomes, and cross-sell manufacturing and commercial infrastructure where the asset fits. The model works as long as the GLP-1 franchise holds pricing power.

Lilly is not the only large pharma running a platform-expansion playbook funded by a single dominant franchise. Gilead faces the same question with lenacapavir, a molecule now anchoring multiple new regimens as Biktarvy exclusivity eventually runs out.

Bull / Base / Bear

• Bull: Retatrutide files Q1 2027 on schedule, two or three acquired assets reach Phase 2 readouts positively, and the stock pushes toward the $1,700 scenario some analysts have modeled.
• Base: Milestone charges continue to weigh on reported EPS through 2027, but revenue growth at 35 to 40% keeps the forward multiple digestible. Stock tracks toward the $1,378 to $1,413 consensus range.
• Bear: One high-profile acquired asset fails Phase 2, Novo Nordisk’s planned 2027 Wegovy price cuts accelerate volume competition, and pricing pressure outpaces volume growth. The acquisition charges stop looking like investments and start looking like write-downs.

What to Watch on October 29

The Q3 call will be the first chance to hear management quantify how many acquired programs have transitioned from deal-close to active clinical development. Watch the acquired IPR&D line, the updated revenue guidance range, and any commentary on retatrutide’s filing timeline. Those three data points will tell investors whether the rollup is proceeding on schedule or starting to bunch up.

The tension between massive upfront capital deployment and uncertain future payoffs is not unique to Lilly. Meta’s pre-commitment strategy of spending before knowing whether its models would succeed raises the same question investors face here.

Bottom Line

Thirteen acquisitions at $32 billion is not diversification for its own sake. It is a deliberate bet that Lilly’s incretin profits, currently generating over $18 billion in annual free cash flow, can fund enough parallel clinical bets to ensure at least several reach commercialization before GLP-1 competition erodes margins. Whether the math works depends less on the deal count and more on which of those thirteen programs produces the next blockbuster. The October 29 call begins to answer that.